Expanding the reach of highly potent cancer therapies with pre|CISION®

We believe in hope
without compromise

Our Science

The pre|CISION® peptide drug conjugate platform. >

Partnering

Avacta is seeking to expand its partnerships for targeted cancer therapies. >

Scrip Awards

We’re delighted to be shortlisted as a finalist at the 2024 Scrip Awards in the ‘Best Oncology R&D Advance’ category >